Vyome (NASDAQ:HIND) Upgraded by Chardan Capital to “Strong-Buy” Rating

Chardan Capital upgraded shares of Vyome (NASDAQ:HIND) to a strong-buy rating in a research note issued to investors on Thursday morning,Zacks reports.

HIND has been the subject of several other research reports. Zacks Research upgraded shares of Vyome to a “hold” rating in a report on Wednesday, May 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Vyome in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.25.

Vyome Stock Performance

NASDAQ:HIND opened at $2.23 on Thursday. The firm’s 50-day moving average is $2.18 and its 200-day moving average is $2.28. The company has a market cap of $15.65 million, a price-to-earnings ratio of -0.66 and a beta of 1.50. Vyome has a 52-week low of $1.75 and a 52-week high of $9.56.

Vyome (NASDAQ:HIND) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.10) earnings per share for the quarter. Vyome had a negative net margin of 3,024.84% and a negative return on equity of 197.33%. The company had revenue of $0.27 million for the quarter. Equities analysts predict that Vyome will post -0.6 EPS for the current year.

Institutional Investors Weigh In On Vyome

A hedge fund recently bought a new stake in Vyome stock. Millennium Management LLC acquired a new stake in shares of Vyome Holdings, Inc. (NASDAQ:HIND) during the fourth quarter, according to its most recent filing with the SEC. The fund acquired 45,144 shares of the company’s stock, valued at approximately $155,000. Millennium Management LLC owned 0.80% of Vyome as of its most recent filing with the SEC. Institutional investors and hedge funds own 22.06% of the company’s stock.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.